Articles by Ansis Helmanis - Pharmaceutical Executive

ADVERTISEMENT
Articles by Ansis Helmanis

IP: Securing a Global Consensus—Can Industry Do It Again?

Oct 1, 2011
By: Ansis Helmanis

Harvey Bale, Jr., MD, former Director-General, IFPMA

Jane Henney: Lessons from the FDA Front Line

Oct 1, 2011
By: Ansis Helmanis

Jane Henney, MD, Former FDA Commissioner

A New Twist in the Cost Curve

Dec 1, 2010
By: Ansis Helmanis

The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?

Managing REMS for the Long Term

Mar 1, 2010
By: Ansis Helmanis

Obligations to fund and support costly studies can extend beyond the period of market exclusivity, giving generics competitors an advantage.

ADVERTISEMENT

Click here